X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15859) 15859
Newsletter (77) 77
Newspaper Article (49) 49
Magazine Article (29) 29
Book Chapter (11) 11
Publication (3) 3
Transcript (3) 3
Book Review (2) 2
Dissertation (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14411) 14411
vincristine - administration & dosage (11877) 11877
antineoplastic combined chemotherapy protocols - therapeutic use (9577) 9577
female (9553) 9553
male (9401) 9401
cyclophosphamide - administration & dosage (7625) 7625
doxorubicin - administration & dosage (6889) 6889
middle aged (6849) 6849
adult (6454) 6454
oncology (5337) 5337
prednisone - administration & dosage (5330) 5330
aged (5138) 5138
chemotherapy (3859) 3859
antineoplastic combined chemotherapy protocols - administration & dosage (3651) 3651
adolescent (3260) 3260
vincristine (3029) 3029
combined modality therapy (2964) 2964
treatment outcome (2862) 2862
hematology (2843) 2843
antineoplastic combined chemotherapy protocols - adverse effects (2616) 2616
methotrexate - administration & dosage (2578) 2578
child (2448) 2448
prognosis (2433) 2433
etoposide - administration & dosage (2230) 2230
cancer (2135) 2135
vincristine - therapeutic use (2059) 2059
vincristine - adverse effects (1998) 1998
remission induction (1963) 1963
child, preschool (1898) 1898
bleomycin - administration & dosage (1870) 1870
rituximab (1561) 1561
follow-up studies (1546) 1546
drug administration schedule (1544) 1544
neoplasm staging (1539) 1539
procarbazine - administration & dosage (1518) 1518
disease-free survival (1500) 1500
retrospective studies (1496) 1496
lymphoma, non-hodgkin - drug therapy (1471) 1471
survival rate (1428) 1428
drug therapy, combination (1427) 1427
prednisolone - administration & dosage (1418) 1418
therapy (1350) 1350
cyclophosphamide (1340) 1340
lymphoma, large b-cell, diffuse - drug therapy (1324) 1324
cisplatin - administration & dosage (1318) 1318
cyclophosphamide - therapeutic use (1305) 1305
infant (1269) 1269
aged, 80 and over (1261) 1261
survival analysis (1255) 1255
cytarabine - administration & dosage (1223) 1223
antineoplastic agents - administration & dosage (1222) 1222
animals (1208) 1208
time factors (1177) 1177
cyclophosphamide - adverse effects (1164) 1164
hodgkin disease - drug therapy (1130) 1130
doxorubicin - adverse effects (1117) 1117
doxorubicin (1107) 1107
doxorubicin - therapeutic use (1069) 1069
prednisone - therapeutic use (1045) 1045
lymphomas (1041) 1041
pediatrics (1005) 1005
dactinomycin - administration & dosage (971) 971
dexamethasone - administration & dosage (957) 957
care and treatment (955) 955
survival (948) 948
prednisone - adverse effects (902) 902
lung neoplasms - drug therapy (894) 894
children (888) 888
radiotherapy (867) 867
prospective studies (840) 840
non-hodgkins-lymphoma (835) 835
dacarbazine - administration & dosage (808) 808
clinical trials as topic (776) 776
mechlorethamine - administration & dosage (769) 769
antineoplastic agents - therapeutic use (759) 759
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (744) 744
vinblastine - administration & dosage (718) 718
recurrence (700) 700
young adult (691) 691
risk factors (689) 689
lymphoma (685) 685
medicine & public health (684) 684
dose-response relationship, drug (675) 675
antibodies, monoclonal, murine-derived - administration & dosage (673) 673
antibodies, monoclonal, murine-derived (668) 668
daunorubicin - administration & dosage (661) 661
etoposide (645) 645
asparaginase - administration & dosage (643) 643
carcinoma, small cell - drug therapy (617) 617
fluorouracil - administration & dosage (617) 617
trial (608) 608
pharmacology & pharmacy (605) 605
lymphoma - drug therapy (599) 599
lymphoma, large b-cell, diffuse - pathology (595) 595
mice (594) 594
tumors (591) 591
multiple myeloma - drug therapy (581) 581
ifosfamide - administration & dosage (580) 580
prednisone (574) 574
leukemia (564) 564
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14076) 14076
Japanese (1036) 1036
German (322) 322
French (272) 272
Russian (225) 225
Spanish (221) 221
Polish (190) 190
Chinese (175) 175
Italian (82) 82
Portuguese (24) 24
Hungarian (21) 21
Dutch (17) 17
Hebrew (12) 12
Czech (9) 9
Croatian (7) 7
Serbian (7) 7
Danish (6) 6
Finnish (4) 4
Turkish (4) 4
Bulgarian (3) 3
Romanian (3) 3
Ukrainian (3) 3
Korean (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 15, pp. 1408 - 1416
A dose-intense infusional chemotherapy program plus rituximab had a high degree of efficacy in patients with primary mediastinal B-cell lymphoma, which is... 
MEDICINE, GENERAL & INTERNAL | AMPLIFICATION | MANAGEMENT | EFFICACY | DOXORUBICIN | SCLEROSIS | CLASSICAL HODGKIN LYMPHOMA | RADIOTHERAPY | EXPRESSION | GERMINAL-CENTER | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Filgrastim | Dose-Response Relationship, Drug | Young Adult | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Kaplan-Meier Estimate | Rituximab | Stroke Volume - drug effects | Etoposide - administration & dosage | Recombinant Proteins - administration & dosage | Disease-Free Survival | Vincristine - adverse effects | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Drugs | Dose-response relationship (Biochemistry) | Usage | Cyclophosphamide | Patient outcomes | Dosage and administration | Lymphomas | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Doxorubicin | Medical research | Nuclear magnetic resonance--NMR | Disease | Review boards | Genes | Etoposide | Prednisone | Radiation therapy | Kinases | Vincristine | Patients | Morbidity | Chemotherapy | Lymphocytes B | Remission | Mutation | Hodgkin's disease | B-cell lymphoma
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | THERAPY | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | LEUKEMIA | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2010, Volume 28, Issue 27, pp. 4199 - 4206
Journal Article
British journal of cancer, ISSN 1532-1827, 2014, Volume 111, Issue 6, pp. 1072 - 1079
Background: Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is a devastating complication; the optimal prophylactic strategy... 
cytarabine | INTERMEDIATE-GRADE | FOLLOW-UP | diffuse large B-cell lymphoma | methotrexate intrathecal | CHEMOTHERAPY | central nervous system | RELAPSE | central nervous system prophylaxis | ONCOLOGY | STANDARD CHOP | NON-HODGKINS-LYMPHOMA | CNS PROPHYLAXIS | AGGRESSIVE LYMPHOMA | RITUXIMAB ERA | ELDERLY-PATIENTS | Recurrence | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Central Nervous System Neoplasms - secondary | Young Adult | Central Nervous System Neoplasms - prevention & control | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Acute Kidney Injury - chemically induced | Retrospective Studies | Doxorubicin - administration & dosage | Injections, Spinal | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Rituximab | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Administration, Intravenous | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Aged | intrathecal | methotrexate | Clinical Study
Journal Article
Journal Article
Blood, ISSN 1528-0020, 2013, Volume 122, Issue 7, pp. 1214 - 1221
Detection of MRD by real-time quantitative PCR and flow cytometry is an important predictor of outcome in patients with Ph+ ALL. 
ADULT PATIENTS | HYPER-CVAD | GENE REARRANGEMENTS | STANDARD-RISK | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | FLOW-CYTOMETRY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLINICAL-SIGNIFICANCE | Piperazines - administration & dosage | Cyclophosphamide - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Thiazoles - administration & dosage | Neoplasm Recurrence, Local - mortality | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Benzamides - administration & dosage | Flow Cytometry | Neoplasm, Residual - diagnosis | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neoplasm, Residual - mortality | Philadelphia Chromosome | Real-Time Polymerase Chain Reaction | Doxorubicin - administration & dosage | Dasatinib | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Pyrimidines - administration & dosage | RNA, Messenger - genetics | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Cytarabine - administration & dosage | Neoplasm, Residual - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Immunoglobulin Heavy Chains - genetics | Lymphoid Neoplasia
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2009 - 2017
Summary Background Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | IDARUBICIN | THERAPY | DOSE ARA-C | PEDIATRIC-PATIENTS | SENSITIVITY | RISK | CHILDHOOD LEUKEMIA | EXPERIENCE | ACCELERATED APPROVAL | ONCOLOGY GROUP | Recurrence | Cyclophosphamide - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Female | Leukocyte Count | Child | Idarubicin - therapeutic use | Mitoxantrone - therapeutic use | Dexamethasone - administration & dosage | Risk Assessment | Kaplan-Meier Estimate | Mercaptopurine - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | United Kingdom | Vidarabine - analogs & derivatives | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Vidarabine - administration & dosage | Complications and side effects | Dosage and administration | Acute lymphocytic leukemia | Drug therapy | Patient outcomes | Mitoxantrone hydrochloride | Studies | Design | Medical research | Chemotherapy | Databases | Cytogenetics | Cancer therapies | Cancer | Ovarian cancer
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2019, Volume 37, Issue 15, pp. 1285 - 1295
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2010, Volume 28, Issue 30, pp. 4630 - 4634
Journal Article